Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer | PTCE Pharmacy Connect

Educational Objectives Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer Faculty: Allison R. Butts, PharmD, BCOP Pharmacist Manager, Oncology Breast Oncology Clinical Pharmacy Specialist Acute Care Pharmacy Services UK HealthCare- Markey Cancer Lexington, Kentucky   Director, PGY2 Oncology Residency Program UK HealthCare Lexington, Kentucky Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Consultant: AstraZeneca; BeyondSpring (one-time advisory boards) Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024. This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.